ACEPODIA BIOTECHNOLOGIES, LIMITED
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
1. ACC (Antibody-Cell Conjugation) technology
2. γδ2 T cell therapy
3. ACE1831
4. ACE2016
5. ACE1708
2. γδ2 T cell therapy
3. ACE1831
4. ACE2016
5. ACE1708
Founded Year
2017
Unified Business No.
66616512
Status
Active
Number of Employees
10
Total Paid-in
Capital
2,900,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2023)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell compatible chemistry to attach tumor-targeting antibodies directly to a variety of immune cell receptors,enhancing the lock between immune and cancer cells and generating highly specific, potent cell therapies without the need for genetic engineering.
Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.
Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.
